Roche presents new data for TECENTRIQ ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017

Roche today announced that new data for TECENTRIQ and updates from across its extensive cancer immunotherapy clinical development programme will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting on 2 June – 6 June in Chicago, Illinois, United States.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news